Given the use of metformin and SGLT2 inhibitors as oral foundation agents, what role are the injectable GLP-1 RA/insulin combination regimens likely to play in guideline-directed care?

Given the use of metformin and SGLT2 inhibitors as oral foundation agents, what role are the injectable GLP-1 RA/insulin combination regimens likely to play in guideline-directed care?

Given the established use of metformin and SGLT2 inhibitors as oral foundation agents, where do you believe the GLP-1 RA/insulin combination regimens, which are injectable, are likely to play the most important role in guideline-directed care?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California